The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | The potential of menin inhibitors in specific molecular subsets of AML & ALL
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, shares her perspectives on the potential of menin inhibitors in the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). These drugs have shown promising results in early-phase studies in heavily pre-treated patients carrying NPM1 mutations and KMT2A gene rearrangements and are currently being evaluated in multiple studies in combination with other agents. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
